Background: ERα and p53 are transcription factors that play important roles in breast cancer. Results: ERα transcriptionally regulates p53, which then modulates DNA damage-induced growth suppression. Conclusion: p53 is a target of ERα and responsible for the sensitivity of ERα-positive breast cancer cells to DNA damage. Significance: Loss of ERα, causing a decrease in p53 expression, could lead to tumors resistant to both anti-estrogen and chemotherapy.
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Estrogen receptor alpha (ERα) and beta (ERβ) are members of the nuclear hormone receptor family and act as transcription factors when bound and activated by their ligand. In breast cells, ERα and ERβ are expressed and share 97% percent identity in their DNA-binding domains and 55% identity in their ligand-binding domains (1). Once activated by 17 beta-estradiol (estrogen), ERα and ERβ form homo and/or heterodimers that regulate expression of shared and unique target genes (2) . An estimated 70% of breast cancer cases express estrogen receptors and thus are classified as ER-positive (3). However, ERα and ERβ have been shown to exhibit opposing effects in breast cancers. ERα expression is high in ER-positive breast cancers and associated with tumor growth (4) . On the other hand, ERβ is expressed at low levels in breast tissue and may play an inhibitory role in tumorigenesis (5) . ERpositive breast cancer generally indicates good patient prognosis and treatment responsiveness with anti-estrogens such as tamoxifen. However, 30-50% of recurrent tumors are resistant to hormone therapy due to loss of ERα expression (6) , which can occur by abnormal methylation of the ERα promoter, pathway inactivation, or spontaneous loss of ERα expression (7) . Importantly, an ER-negative tumor status is associated with aggressive tumor growth, increased invasiveness, poor patient prognosis, and loss of p53 function (8) .
The tumor suppressor p53 is activated by genotoxic stress to induce target genes for cell cycle arrest, DNA repair, and apoptosis (9) . p21, a cyclin dependent kinase inhibitor, is a major p53 target gene that blocks cell cycle progression at G1/S transition to allow DNA repair (10) . If damages are unrepairable, p53 induces several apoptotic target genes, such as PUMA, Bax, and Noxa, leading to programmed cell death (9) . Under normal cellular conditions, p53 is kept inactive by its target, murine double minute 2 (MDM2), a RING-finger E3 ubiquitin ligase (11) . Indicative of its importance in genome stability, p53 is inactivated in more than 50% of all human cancers (12) . Surprisingly, only 20% of breast cancers contain mutated p53, which suggests that other mechanisms are involved in inactivating p53 function (13) .
Evidence showed that expression of ERα is correlated with the status of p53 (14) (15) . It has been shown that knockdown of p53 decreases, whereas overexpression of p53 increases, ERα expression in ER-positive MCF7 breast cancer cells (14) . Consistently, DNA damage increases ERα expression in mammary tumors in a p53-dependent manner (15) . Indeed, it has been shown that p53 regulates ERα transcription via recruiting several transcription factors including CBP and Sp1 to the ERα promoter (15) . However, physical interaction between p53 and ERα interferes with each other's activities to regulate gene expression (16) (17) . Interestingly, it has been reported that upon treatment with estrogen, p53 expression is enhanced (18), suggesting that ERα may regulate p53 expression. In this study, we found that knockdown of ERα decreases, whereas ectopic expression of ERα increases, p53 transcription. In addition, we showed that ERα binds to and activates the p53 promoter via two ERE half-sites. Moreover, the p53 promoter is activated by estrogen. Finally, we showed that knockdown of ERα attenuates, whereas overexpression of ERα enhances, DNA damage-induced growth suppression in a p53-dependent manner. Taken together, our data suggest that p53 is a direct transcriptional target of ERα and modulates DNA damage-induced growth suppression in ERα-positive breast cancer cells.
MCF7 cDNA with forward primer, 5'-GGACCACCATGTACCCATACGATGTTC CAGATTACGCTACCATGACCCTCCACA CCAAAGCATC-3' and reverse primer, 5'-GAAGATCTCCACCATGCCCTCTAC-3'. Similarly, HA tagged wild-type ERβ in pCMV was generated using forward primer, 5'-GGACCACCATGTACCCATACGATGTTC CAGATTACGCTGATATAAAAAACTCAC CATC-3' and reverse primer, 5'-CTCGAGTCACTGAGACTGTGGGTTCTG GG-3'. To generate untagged wild-type ERα in pcDNA4 for tetracycline-inducible expression (Invitrogen), the cDNA fragment was amplified from an ERα cDNA clone (GeneBank Accession: BC128573.1; Openbiosystems) with forward primer, 5'-AGGAATTCACCATGGAGCGGATCCCCA GCG-3', and reverse primer,
To generate a construct for the inducible expression of ERα shRNA, two oligonucleotides, 5′-GATCCCCAGTTTGTGTGCCTCAAATC TTCAAGAGAGATTTGAGGCACACAAA CTTTTTTGGAAA-3′ and 5′-AGCTTTTCCAAAAAAGTTTGTGTGCC TCAAATCTCTCTTGAAGATTTGAGGC ACACAAACTGGG-3′, were designed to target ERα exon 6 (in boldface). The oligonucleotides were annealed and cloned into pBabe-H1 as previously described (19). The resulting vector was designated pBabe-H1-siERα. The pBabe-U6-sip53 construct expressing p53 shRNA was described previously (20). To generate pGL2 luciferase reporters under control of the p53 promoter (nt -1998 to +73 designated p53-P-2kb and nt -593 to +73 designated p53-P-593), genomic DNA fragments were amplified from MCF7 cells with forward primer (5'-ATGGGTACCAAGTGTAGGGCTAGGGCT  G-3'  or  5'-TTGGTACCGCTTCAGACCTGTCTCCCTC  ATTC-3') and  reverse primer  (5'-ACTCTCGAGTGGCTCTAGACTTTTGAG  AAGCTC-3') . p53 promoter internal deletion mutants were generated by PstI and PvuII (NEB) restriction enzyme digest and religation according to manufacturer's instruction and designated p53-P-PstI and p53-P-PvuII, respectively.
To generate individual wild-type or mutant ERE half-sites cloned upstream of the minimum cfos promoter in the luciferase reporter OFLuc reporter vector (21), genomic DNA fragments were amplified from MCF7 cells with the following primer sets: -1828 forward primer, 5'-GGGGAAGCTTTGAAAATCTCGGGGGTG GTCAG-3' and reverse primer, 5'-GGGGAGATCTTCGATTTCTCAGTGGTTC CTGGTCAG-3'; -1828M forward primer, 5'-GGGGAAGCTTTGAAAATCTCGGGGGTG TACAG-3' and reverse primer, 5 '-GGGGAGATCTTCGATTTCTCAGTGGTTC  CTGTACAG; -1611 forward primer, 5'-GGGGAAGCTTAGGCCTGGAGAAGTGG  GTCT-3'  and  reverse  primer,  5'-GGGGAGATCTTAAGTGGTGATGGCAG-3';  -1611M  forward  primer,  5'-GGGAAGCTTAGGCCTGGAGAAGTGGTA  CTCAGGATT-3' and reverse primer, 5'-GGGGAGATCTTAGCTCCGGACTGCTGT  ACTTCAGTAC-3'; -1248 forward primer,  5'-GGGGAAGCTTAGCCACAGGATCTGGGG  ACA-3'  and  reverse  primer,  5'-GGGGAGATCTCACGCTTCCCCGATGA-3';  -1224  forward  primer,  5'-GCGGAAGCTTCAGTTCAGAGTCC-3' and  reverse primer, 5'-GGGCAGATCTTAGCTCCGGACTGCTG-3'. Added restriction enzyme sites are shown in italic. Wild-type and mutant ERE sites are shown in boldface.
Cell Lines-MCF7 and ZR-75-1 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37 °C with 5% CO 2 . MCF7-TR-7, which expresses the tetracycline repressor, was generated in our laboratory (22). To generate cell lines that inducibly express wild-type ERα, MCF7-TR-7 cells were transfected with pcDNA4-ERα using Lipofectamine 2000 (Invitrogen), and selected with medium containing 200 μg/ml Zeocin. To generate cell lines in which ERα and/or p53 are inducibly knocked down, MCF7-TR-7 cells were transfected with pBabe-H1-siERα and/or pBabe-U6-sip53 and selected with 0.5 μg/ml puromycin. To generate cell lines that inducibly express wild-type ERα and in which p53 is knocked down, MCF7-TR-7 cells were transfected with pcDNA4-ERα and pBabe-U6-sip53 and selected with 200 μg/ml Zeocin and 0.5 μg/ml puromycin. The resulting cell lines were designated MCF7-ERα, MCF7-ERα-KD, MCF7(p53-KD)-ERα-KD, and MCF7(p53-KD)-ERα, respectively.
Luciferase Reporter Assay-The dual luciferase assay was performed in triplicate using MCF7 cells according to the manufacturer's instruction (Promega). Cells were mock-treated or treated with 17β-estradiol (Sigma) or ICI 182, 780 (Sigma) for 24 h prior to transfection. The fold change in relative luciferase activity was determined by the luciferase activity induced by ERα or ERβ, divided by luciferase activity induced by an empty pcDNA3 vector.
Chromatin RTqPCR and relative quantification of mRNA were performed as previously described (25).
siRNA -To transiently knock down
ERα and/or p53, cells were transfected with ERα siRNA (5'-GGAUUUGACCCUCCAUGAU-3'; Dharmacon) and/or p53 siRNA (5'-GGAAAUUUGCGUGUGGAGU-3'; Qiagen) using siLentFect (BioRad) according to the manufacturers instructions. The non-targeting scramble siRNA (Dharmacon) was used as a control.
RESULTS
p53 expression is regulated by ERα ER-positive breast cancer cells generally contain wild-type p53 and rely on estrogen for proliferation (26). Interestingly, high levels of estrogen are associated with increased p53 expression in breast cancer cells under a stress condition (27). Since ERα, the main estrogen receptor in breast tumors, is activated by estrogen to induce target gene expression (28), we determined whether ERα affects p53 expression.
To test this, we generated multiple MCF7 cell lines in which ERα can be inducibly knocked down. The MCF7 cell line is known to express ERα and wild-type p53. As shown in Fig. 1A , ERα was efficiently knocked down in clones 4, 11, and 33. We found that the level of p53 protein was markedly decreased upon knockdown of ERα in clone 11 (Fig. 1B, p53 panel, compare lane 1 with 2). In addition, ERα-knockdown (KD) inhibited stabilization of p53 induced by treatment with camptothecin (CPT) (Fig. 1B , compare lanes 3, 5, 7, and 9 with 4, 6, 8, and 10, respectively), doxorubicin (Dox) (Fig. 1C , compare lanes 3, 5, and 7 with 4, 6, and 8, respectively), and Nutlin-3 (Nut-3) (Fig. 1D , compare lanes 3 and 5 with 4 and 6, respectively).
CPT and Dox are topoisomerase I and II inhibitors, respectively, and Nut-3 is an MDM2 antagonist, all of which stabilize and activate p53 (29-30). Morever, we found that attenuation of p53 stabilization by ERα-KD led to decreased induction of p53 target genes, p21 and MDM2 ( Fig. 1B-D) . To confirm this, the same experiments were performed in clones 4 and 33 and similar results were observed ( Fig.  1E-F ). To rule out potential off-target effects, ERα was transiently knocked down by another siRNA, which is different from that used for cell line generation. Consistently, we found that transient knockdown of ERα resulted in a decrease of p53, MDM2, and p21 regardless of treatment with Dox or Nut-3 ( Fig. 1G , compare lanes 1, 3, and 5 with 2, 4, and 6, respectively). Moreover, to rule out a potential cell type-specific effect, ERα was transiently knocked down in ZR-75-1, an ERpositive breast cancer cell line containing wild-type p53 (31). Again, we showed that knockdown of ERα led to a decreased level of p53 protein (Fig. 1H) .
Next, we examined whether the decrease in p53 protein was due to a decrease in p53 transcript. As a positive control, we tested pS2, which is known to be transcriptionally regulated by estrogen receptor (32). We found that knockdown of ERα resulted in a decrease of ERα, pS2, and p53 transcripts in clone 4 ( Fig. 2A) . Similarly, transient knockdown of ERα by another siRNA also resulted in a decrease of ERα, pS2, and p53 transcripts (Fig. 2B) . In addition, quantitative real time RT-PCR was performed and confirmed that knockdown of ERα decreased p53 transcript in clone 4 ( Fig. 2C ). Together, these data suggest that p53 is transcriptionally regulated by ERα.
ERα binds to ERE half sites on the p53 promoter to induce p53 expression ERα, a nuclear hormone receptor, regulates gene expression by binding to consensus and nonconsensus estrogen response elements (EREs) on target gene promoters. A consensus ERE is composed of two palindromic half-sites separated by 3 nucleotides (nt), 5′-GGTCAnnnTGACC-3′ (where n represents any nucleotide) (33). However, ERα is also able to bind to and activate target gene promoters containing imperfect or truncated ERE sites (34). In addition, ERα can activate gene expression by binding to enhancer sites located at a distance of > 100 kb from the transcriptional start site of estrogen-regulated target genes (35). Thus, we analyzed the genome-wide ChIP-ENCODE database, which contains a comprehensive library of transcription factor interactions on the human genome (36). Probing of this data set showed an ERα interaction on the p53 proximal promoter region. A closer look at the p53 promoter sequence revealed four potential ERE half-sites (Fig. 3A, p53 panel) . To determine whether ERα binds to the p53 promoter in vivo, a chromatin immunoprecipitation (ChIP) assay was performed using chromatin collected from MCF7 cells. The binding of ERα to the pS2 gene, a well-defined target of ERα, served as a positive control (37). The binding of ERα to the GAPDH promoter was measured as a non-specific binding control. We showed that ERα bound to the p53 and pS2 promoters, but not the GAPDH promoter (Fig. 3B) .
Next, to determine which of the four potential ERE half-sites is responsive to ERα, a luciferase reporter under the control of the p53 promoter (nt -1998 to +73), which contains all four ERE half-sites (at nt -1224, -1248, -1611, and -1828), was constructed and designated p53-P-2kb (Fig. 3C , left panel). In addition, luciferase reporters containing one, two, or none of the ERE half-sites were constructed and designated p53-P-PstI, p53-PPvuII, and p53-P-593 (Fig. 3C, left panel) . We found that ERα induced a 4-fold increase in luciferease activity for p53-P-2kb and p53-P-PstI, a 2.7-fold increase for p53-P-PvuII, but no increase for p53-P-593 (Fig. 3C, right  panel) . These results suggest that the ERE half-sites at nt -1611 and -1828 are important for ERα activation of p53 transcription. To confirm this, the four potential ERE half-sites were individually cloned into the OFLuc reporter vector (21), which contains a minimal c-fos promoter, and the resulting constructs were designated OFLuc-1828, OFLuc-1611, OFLuc-1248, and OFLuc-1224 (Fig. 3D, left panel) . We showed that upon expression of ERα, luciferase activity was increased 4-fold for OFLuc-1611, 3-fold for OFLuc-1828, 2-fold for OFLuc-1248, and less than 50% for OFLuc-1224 (Fig. 3D, right  panel) . To further test the ERE half sites at nt -1828 and -1611, the ERE consensus sequence for each half-site was mutated and the resulting reporters carrying a mutant ERE were designated as OFLuc-1828M and OFLuc-1611M, respectively (Fig. 3D, left  panel) . We showed that the luciferase activity was not increased by ERα for OFLuc-1828M and little if any for OFLuc-1611M (Fig. 3D , right panel). Taken together, these results indicate that the ERE half-sites located at nt -1611 and -1828 on the p53 promoter are primarily responsible for ERα activation of p53 transcription.
Estrogen, an ERα ligand, induces a conformational change of ERα and then promotes ERα dimerization and binding to ERE sites (38). To test whether the p53 promoter is estrogen-responsive, MCF7 cells were pretreated with estrogen or anti-estrogen ICI 182,780 (Fulvestrant). We showed that estrogen enhanced, but ICI 182,780 suppressed, the ability of ERα to increase the luciferase activity under the control of the p53 promoter (Fig. 3E) .
Although ERα and ERβ recognize the same EREs on target gene promoters, they are capable of regulating both common and distinct sets of target genes (34,39). Thus, we examined whether ERβ regulates p53 transcription. Surprisingly, we found that unlike ERα, ERβ had no effect on luciferease activity for p53-P-2kb (Fig. 3F) . Together, we concluded that ERα regulates p53 transcription through multiple ERE half-sites on the p53 promoter.
Knockdown of ERα desensitizes cells to DNA damage-induced growth suppression in a p53-dependent manner
It is well established that, when activated by DNA damage, p53 induces target genes for cell cycle arrest and apoptosis (9) . In contrast, it is well known that ERα induces target genes that promote cell growth (40). To determine the biological function of p53 expression induced by ERα, colony formation assay was performed to examine the effect of ERα-KD on cell proliferation in MCF7 cells, in which ERα can be inducibly knocked down. We found that knockdown of ERα decreased the size of colonies formed by MCF7-ERα-KD-4 cells (Fig. 4A , top panel, mock-treatment column). The overall number of colonies and cell density were quantified to measure the level of cell proliferation. We found that ERα-KD did not change the number of colonies, but inhibited cell proliferation, (Fig. 4A , compare middle panel to bottom panel, mocktreatment column). In addition, we found that when MCF7 cells were treated with CPT and Dox, the number of colonies and overall cell density were markedly decreased (Fig. 4A , top panel, compare CPT and Dox columns with mock-treatment column). However, the number of colonies and overall cell density formed by ERα-KD cells were significantly increased compared with that formed by control cells upon treatment with CPT or Dox (Fig. 4A , compare middle panel with bottom panel, CPT and Dox columns). Similar results were obtained with MCF7-ERα-KD-11 cells (Fig. 4B) .
To further determine the cellular response to DNA damage when ERα is knocked down, we analyzed several p53 target genes in cell cycle arrest and cell death including p21, MDM2, PolH, PUMA, and MIC-1 (41-45). We found that knockdown of ERα led to a decrease in the protein levels of p21, MDM2, PolH, PUMA, and MIC-1 in MCF7-ERα-KD-4 and -11 cells treated with CPT and Dox (Fig. 4C, compare lanes 3, 5, 9 , and 11 with 4, 6, 10, and 12, respectively).
To determine if the decreased sensitivity of ERα-KD cells to DNA damage is due to p53, we generated multiple MCF7 cell lines, designated MCF7(p53-KD)-ERα-KD, in which p53 was stably knocked down and ERα can be inducibly knocked down. As shown in Fig. 5A , both ERα and p53 were knocked down in clones 13, 15, and 18. The levels of ERα and p53 were also measured in ERα-KD clone 11 (Fig. 5A) , which was used as a control. Next, colony formation assay was performed with MCF7(p53-KD)-ERα-KD cell lines (clones 13 and 15). We found that upon knockdown of p53, ERα-KD had no effect on the size and number of colonies regardless of DNA damage (Fig. 5B-C) . In addition, we showed that unlike in p53-proficient cells (Fig. 4C) , the expression of p53 target genes was not affected by ERα-KD in p53-deficient cells treated with CPT and Dox (Fig. 5D) . Similarly, we showed that expression of p53 along with its targets, p21, MDM2, PolH, PUMA, and MIC-1, was decreased by ERα-KD (Fig. 5E , compare lane 3 with 4), which was diminished if not abrogated by p53-KD in ZR-75-1 cells treated with Dox (Fig. 5E , compare lane 7 with 8, respectively). Together, we conclude that knockdown of ERα desensitizes MCF7 cells to DNA damage-induced growth suppression in a p53-dependent manner.
Ectopic expression of ERα sensitizes MCF7 cells to DNA damage-induced growth suppression in a p53-dependent manner
Overexpression of ERα is a hallmark of ER-positive breast cancer (46) . Interestingly, overexpression of ERα is also correlated with higher levels of p53 (47) (48) and a favorable prognosis (6) 
We showed that ectopic expression of ERα led to increased accumulation of p53 in MCF7 cells upon treatment with CPT (Fig. 6B, p53 panel, compare lanes 3 and 5 with 4 and 6, respectively; Fig. 6C, p53 panel, compare lane 3 with 4), Dox ( Fig. 6D-E, p53 panel, compare lane 3 with 4), or Nut-3 (Fig. 6F,  p53 panel, compare lanes 3 and 5 with 4 and 6, respectively). In addition, the enhanced level of p53 by ERα overexpression was transcriptionally active as MDM2, a p53 target, was also increased (Fig. 6B and 6F , MDM2 panel, compare lanes 5 with 6; Fig.  6C-E, MDM2 panel, compare lanes 3 with 4) . Next, colony formation assay was performed to examine the effect of ERα overexpression on cell growth. We found that overexpression of ERα in MCF7 cells enhanced cell proliferation (Fig. 6G-H , mock-treatment panels) consistent with previous results (49) . However, ERα-overexpressing cells were more sensitive to treatment with CPT and Dox compared to control cells (Fig. 6G-H , CPT and Dox panels).
To determine whether the increased sensitivity of ERα-overexpressing cells to DNA damage was dependent on p53, we generated multiple MCF7 cell lines, designated MCF7(p53-KD)-ERα, in which p53 was stably knocked down and ERα can be inducibly expressed. Western blot analysis showed that p53 was undetectable, whereas ERα was inducibly expressed in MCF7(p53-KD)-ERα (clones 49 and 70) compared to that in MCF7-TR-7 cells (Fig. 7A) . Next, colony formation assay was performed and showed that the increased sensitivity of ERα-overexpressing cells to DNA damage was abrogated by p53-KD (Fig. 7B-C) .
DISCUSSION
The p53 tumor suppressor is commonly mutated in over 50% of human cancers (12) . However, the overall frequency of p53 mutations in breast cancers is significantly lower than in other type of cancers (13) . Inactivation of p53 in cancers maintaining wild-type p53 allele could be achieved via alterations in upstream regulators and downstream effectors (50) . For example, positive regulators of p53, such as ATM/Chk2 and ARF, have been found to be inactivated, whereas negative regulators of p53, such as MDM2, have been found to be overexpressed (51) (52) .
In addition, p53 target genes, such as PIG8 (a pro-apoptotic factor) and 14-3-3σ (a G2/M arrest regulator), are often inactivated in breast cancers (53) (54) . Importantly, it has been shown that reduced basal level of p53 mRNA due to loss of HoxA5 expression is correlated with primary breast carcinomas (55) . Indeed, p53 is a direct target of HoxA5 (55) .
Reports also showed that p53 is transcriptionally activated by c-Jun and c-Fos through the AP-1 site, p50 NF-κB1 and p65 RelA through the NF-κB motif, and c-myc/Max/USF through the Ebox element (56) . During the time we were preparing this manuscript, one report showed that Oldenlandia diffusa extract stimulates ERα association with Sp1 at the GC-rich motif in the proximal p53 promoter (57). However, whether ERα directly regulates p53 transcription is unclear. Here, we found that knockdown of ERα results in reduced expression of p53 protein and mRNA (Figs. 1  and 2 ). In addition, we found that ERα activates p53 transcription via binding to ERE half-sites on the p53 promoter (Fig. 3) . Antiestrogen ICI 182,780 competes with estrogen for binding to ERα, promotes ERα degradation, disrupts nuclear localization and dimerization of ERα, and reduces ERα binding to ERE sites (38,58). Thus, ICI 182,780 attenuates ERα transcriptional activity and also reduces steady-state levels of ERα (58) (59) . Consistently, we showed that activation of the p53 promoter by ERα is enhanced by estrogen, but reduced by ICI 182,780 (Fig. 3E) . These data indicate that p53 is a direct target of ERα. Importantly, it has been shown that ERα is regulated by p53 (14) (15) . Therefore, our findings provide new insights into a positive feedback loop between p53 and ERα.
ERα, a nuclear hormone receptor and a transcription factor, is involved in several physiological processes, such as development of the female reproductive system, metabolism, and bone homeostasis (60) . However, enhanced proliferation of ERpositive cells by ERα contributes to mammary tumorigenesis (61) .
As a result, ERα inhibitors, such as tamoxifen, have been successfully developed for breast cancer treatment (62) . Importantly, the mortality for ER-positive breast cancer, when treated with anti-estrogen and adjuvant chemotherapy, is markedly decreased (63) (64) . However, the underlying mechanism is not clear. As a master mediator of DNA damage signals to induce cell cycle arrest and apoptosis, the status of p53 predicts a good outcome following chemotherapy (65) (66) . However, the extent of p53 involvement in endocrine therapy and chemotherapy in breast cancers is still uncertain (67) . Here, we found that ERα-KD cells with impaired p53 expression are more resistant (Fig. 4) , whereas ERα-overexpressing cells with elevated p53 expression are more sensitive (Fig. 6) , to DNA damage-induced growth suppression as compared with controls. We also showed that knockdown of p53 diminishes, if not abrogates, the pro-survival activity of ERα-KD and the anti-survival activity of ERα-overexpression upon treatment with DNA damage (Figs. 5 and 7) . Moreover, we showed that expression of p53 target genes in cell cycle arrest (p21) and in cell death (PolH, PUMA, and MIC-1) was decreased by ERα-KD in p53-proficient (Figs. 4C and 5E), but not in p53-deficient cells (Fig. 5D-E) . Thus, our data indicate that in addition to hormone therapy, ERα is implicated in chemotherapy via regulating the p53 pathway.
In clinical studies, ER-positive breast cancer is defined as having a statistically significant chance of responding to hormone therapy with a positive outcome. ER-positive cases make up 70% of all invasive breast cancer diagnoses (68) . However, 30-40% of ER-positive breast cancer patients can experience a decrease in ERα activity from hormone treatment (69) .
Interestingly, evidence showed that p53 alteration has found to be correlated with ER-negative and high grade breast tumors (70) . Together, we hypothesized that due to a positive feedback regulatory loop between ERα and p53, loss of ERα would lead to a decrease in p53 expression, which in turn could lead to formation of a more aggressive tumor refractory to both anti-estrogen and chemotherapy. Therefore, further exploration of the relationship between ERα and p53 in breast cancers will improve our understanding and practical management of different types of breast tumors. 
